The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Merck KGaA
Phase II study of tepotinib in NSCLC patients with METex14 mutations.
 
Paul K. Paik
Honoraria - Abbvie; Celgene; Lilly; Takeda
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Celgene; Lilly
Research Funding - Celgene; EMD Serono
Travel, Accommodations, Expenses - EMD Serono
Other Relationship - Takeda
 
Remi Veillon
Consulting or Advisory Role - MSD Oncology; Novartis; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; MSD Oncology; Roche
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Merck KGaA (Inst); Roche (Inst); Takeda (Inst)
 
Alexis B. Cortot
Honoraria - Bristol-Myers Squibb; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD; Pfizer; Roche
Research Funding - Merck Serono (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Enriqueta Felip
Consulting or Advisory Role - Abbvie; AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Guardant Health; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Speakers' Bureau - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Research Funding - EMD Serono (Inst); Merck (Inst)
 
Hiroshi Sakai
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Merck KGaA; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical
 
Julien Mazieres
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly/ImClone; MSD; Novartis; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer; Roche
 
Frank Griesinger
Honoraria - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; MSD; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; MSD; Novartis; Pfizer; Roche/Genentech; Takeda
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst)
 
Leora Horn
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; EMD Serono; Genentech; Incyte; Janssen; Lilly; Merck; Tesaro; Xcovery
Research Funding - Boehringer Ingelheim (Inst); Xcovery (Inst)
Other Relationship - Boehringer Ingelheim; Bristol-Myers Squibb
 
Helene Senellart
No Relationships to Disclose
 
Jan P. Van Meerbeeck
Consulting or Advisory Role - Boehringer Ingelheim; Merck; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Roche
 
Javier de Castro Carpeño
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dome; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dome; Roche
 
Jyoti D. Patel
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca; Takeda Science Foundation
 
Marina Chiara Garassino
Honoraria - AstraZeneca/MedImmune; GlaxoSmithKline; MSD Oncology; MSD Oncology
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Roche; Takeda; Tiziana Life Sciences
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Celgene; Incyte; MSD Oncology; Roche; Takeda
Research Funding - AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Masahiro Morise
Honoraria - AstraZeneca; Chugai Pharma; Lilly; MSD; Ono Pharmaceutical; Pfizer
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Kissei Pharmaceutical (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Chugai Pharma; Lilly; MSD; Pfizer
 
Niels Reinmuth
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Pfizer; Roche; Takeda
Speakers' Bureau - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Pfizer; Roche; Takeda
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Roche; Takeda
 
Santiago Viteri
No Relationships to Disclose
 
Takaaki Tokito
No Relationships to Disclose
 
Tomohiro Sakamoto
No Relationships to Disclose
 
Jürgen Scheele
No Relationships to Disclose
 
Xiuning Le
Consulting or Advisory Role - AstraZeneca; Lilly